通过干扰素对慢性乙型肝炎发生转阴病例分析(2)
聚乙二醇干扰素a-2a是有效的治疗慢性乙型肝炎的药物;HBsAg的转阴与患者的年龄,HBV基因型,基线血清HBV DNA和HBsAg滴度等有一定的关系,合理选择病例,监测HBsAg滴度变化对预测患者HBsAg的转阴率有一定的帮助。
参考文献
[1] Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet 2003;362:2089-2094
[2] 中华医学会肝病学分会、感染病学分会.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13:881-891
[3] Cheong JY.Management of chronic hepatitis B in treatment-naive patients. Korean J Gastroenterol. 2008 ;51:338-345
[4] Anand AC, Puri P. Treatment of chronic hepatitis B: will entecavir and telbivudine do the trick?Trop Gastroenterol. 2008;29:71-75
[5] Cooksley WG, Piratvisuth T, Lee SD, et al. Peginterferon a-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. Journal of Viral Hepatitis,2003; 10: 298-305
[6] Chan HL.Wong VW.Chim AM. et al.Treatment of patients with chronic hepatitis B who have failed previous antiviral treatment with pegylated interferon alpha2a.Antiviral therapy;2008;13:555-562
[7] Pawlotsky JM.Virologic techniques for the diagnosis and monitoring of hepatitis B.Gastroenterol Clin Biol.2008;32:S56-S63
[8] Morillo VR, Madrazo BA, Gil MV,et al.Drugs treatment of hepatitis B.Farmacia Hospitalaria,2008;32(4):234-248
[9] Oommen PT,Wirth S,Wintermeyer P,et al. Relationship between viral load and genotypes of hepatitis B virus in children with chronic hepatitis B. Journal of Pediatric Gastroenterology and Nutrition,2006,43:342-347
[10] Chen J, Wang Z. Guo Y,et al. Serum HBsAg changes in HBeAg positive chronic hepatitis B patients with continuous viral load reductions during treatment with adefovir or peg-interferon-alpha-2a. Antiviral research,2008;81: 88-91
[11] Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferonalfa-2a in HBeAg-negative patients. Hepatology,2009,49:1-7
[12] Asselah T, Lada O, Boyer N, et al.Treatment of chronic hepatitis B. Gastroenterologie clinique et biologique,2008;32: 749-768
作者单位:510000 广东省广州中山大学附属第三医院, 百拇医药(卢建溪 舒 欣 曹 红)
参考文献
[1] Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet 2003;362:2089-2094
[2] 中华医学会肝病学分会、感染病学分会.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13:881-891
[3] Cheong JY.Management of chronic hepatitis B in treatment-naive patients. Korean J Gastroenterol. 2008 ;51:338-345
[4] Anand AC, Puri P. Treatment of chronic hepatitis B: will entecavir and telbivudine do the trick?Trop Gastroenterol. 2008;29:71-75
[5] Cooksley WG, Piratvisuth T, Lee SD, et al. Peginterferon a-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. Journal of Viral Hepatitis,2003; 10: 298-305
[6] Chan HL.Wong VW.Chim AM. et al.Treatment of patients with chronic hepatitis B who have failed previous antiviral treatment with pegylated interferon alpha2a.Antiviral therapy;2008;13:555-562
[7] Pawlotsky JM.Virologic techniques for the diagnosis and monitoring of hepatitis B.Gastroenterol Clin Biol.2008;32:S56-S63
[8] Morillo VR, Madrazo BA, Gil MV,et al.Drugs treatment of hepatitis B.Farmacia Hospitalaria,2008;32(4):234-248
[9] Oommen PT,Wirth S,Wintermeyer P,et al. Relationship between viral load and genotypes of hepatitis B virus in children with chronic hepatitis B. Journal of Pediatric Gastroenterology and Nutrition,2006,43:342-347
[10] Chen J, Wang Z. Guo Y,et al. Serum HBsAg changes in HBeAg positive chronic hepatitis B patients with continuous viral load reductions during treatment with adefovir or peg-interferon-alpha-2a. Antiviral research,2008;81: 88-91
[11] Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferonalfa-2a in HBeAg-negative patients. Hepatology,2009,49:1-7
[12] Asselah T, Lada O, Boyer N, et al.Treatment of chronic hepatitis B. Gastroenterologie clinique et biologique,2008;32: 749-768
作者单位:510000 广东省广州中山大学附属第三医院, 百拇医药(卢建溪 舒 欣 曹 红)